Polynovo Limited · ASX:PNV
Polynovo — FY2019 Earnings Presentation
11 slides from Polynovo's earnings presentation, Aug 22, 2019
Slide 1: PolyNovo Limited FY19 Annual Report Brokers' Presentation
PolyNovo Limited FY 19 Annual Report Brokers’ Presentation 22 August 2019 ASX: PNV
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this pr
Slide 3: Highlights of FY19 to August 2019
Highlights of FY19 to August 2019 Page 3
Slide 4: Driving expansion
Driving expansion • Purchased adjacent building for hernia and breast device manufacturing • Purchase / commissioning of new machinery for hernia and breast device manufacturing • Appointed direct sales person in UK sales pending CE Mark • New regulatory approvals in India, Malaysia and Singapore •
Slide 5: Depth of Talent
Depth of Talent • Increased headcount to 36 (June 18) 47 (June 19) 60 (August) • Appointment of Jan Gielen CFO • Appointment of Ashok Srinivasan COO • Appointment of Monica Benyk as HR manager • Appointed 1st sales person in UK/Ireland in anticipation of CE Mark approval (imminent) • Appointed Senio
Slide 6: Improving patient's lives
Improving patient’s lives Noah doesn’t remember the sound of the explosion. But he does remember waking up on fire as the flames burned through his gasoline-soaked skin. Noah received 3rd degree burns to over half of his body potentially altering the trajectory of this young man’s life. Thanks to th
Slide 7: Improving peoples lives
Improving peoples lives After the train crushed his foot, Malcom was told a below the knee amputation was the only solution. That outcome wasn’t acceptable to Malcom or his surgeon. BTM helped to re-cover his exposed structures so his body could heal. Today he stands tall despite the injury that kno
Slide 8: Clinical Trial update
Clinical Trial update • CE Burn trial is complete with final publication of results due by end of CY 19 • BARDA funded Feasibility trial results will be published ~ March 2020 sites were • Wake Forest Baptist Health, Winston-Salem, • University of Tennessee Medical Centre, Memphis • University of Ca
Slide 9: Strategy for FY20
Strategy for FY20 • Significant expansion of sales of BTM in the US, Australia and New Zealand. • Expansion of sale territories • Exciting new product pipeline in breast and hernia. • Increasing manufacturing capacity commission hernia production • File Hernia US FDA 510(K) • Achieve US DoD sales •
Slide 10: Top 20 shareholders
Top 20 shareholders Shares % 1 HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 58,830,306 8.9 2 J P MORGAN NOMINEES AUSTRALIA PTY LIMITED 33,667,129 5.09 3 MOGGS CREEK PTY LTD 16,000,000 2.42 4 MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED 14,962,331 2.26 5 CITICORP NOMINEES PTY LIMITED 14,626,121 2.21 6
Slide 11: It takes a team
It takes a team i PolyNovo: